Literature DB >> 31762335

Anorectic state of obesity medications in the United States. Are leaner times ahead?

Xinyi Li1,2, Nicholas T Bello1,2,3.   

Abstract

Introduction: Obesity is considered to be a chronic disease. Currently there are five prescription-only medications on the US market for the long-term management of obesity. However, these medications are underutilized by obese or overweight individuals seeking medical assistance for weight management.Areas covered: This special report provides an overview of the emerging obesity pharmacotherapies based on the data available from recruiting and active phase II/III trials from a registry of clinical trials. The authors also give their expert opinion and provide their future perspectives on the treatment of obesity based on what is known.Expert opinion: Despite obesity being a chronic condition affecting 40% of the US population, there is a low demand for obesity medications in the US market. Although the potential obesity medications that are currently being investigated in phase II/III clinical trials are promising, it is unclear whether the future pharmacotherapies will be enough to meet the health care need.

Entities:  

Keywords:  MEDI0382; Orlistat; dapagliflozin; liraglutide; lorcaserin; naltrexone/bupropion; phentermine/topiramate; semaglutide; setmelanotide; tesofensine

Mesh:

Substances:

Year:  2019        PMID: 31762335      PMCID: PMC6980700          DOI: 10.1080/14656566.2019.1692815

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  39 in total

1.  Under-reporting of adverse effects of tesofensine.

Authors:  Arne Astrup; Sten Madsbad; Leif Breum; Thomas J Jensen; Jens P Kroustrup; Thomas M Larsen
Journal:  Lancet       Date:  2013-07-13       Impact factor: 79.321

2.  Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity.

Authors:  Faidon Magkos; Gemma Fraterrigo; Jun Yoshino; Courtney Luecking; Kyleigh Kirbach; Shannon C Kelly; Lisa de Las Fuentes; Songbing He; Adewole L Okunade; Bruce W Patterson; Samuel Klein
Journal:  Cell Metab       Date:  2016-02-22       Impact factor: 27.287

3.  Can we win the war on obesity with pharmacotherapy?

Authors:  Juliet D Gotthardt; Nicholas T Bello
Journal:  Expert Rev Clin Pharmacol       Date:  2016-09-13       Impact factor: 5.045

4.  Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.

Authors:  Patrick M O'Neil; Andreas L Birkenfeld; Barbara McGowan; Ofri Mosenzon; Sue D Pedersen; Sean Wharton; Charlotte Giwercman Carson; Cecilie Heerdegen Jepsen; Maria Kabisch; John P H Wilding
Journal:  Lancet       Date:  2018-08-16       Impact factor: 79.321

5.  One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.

Authors:  N Finer; W P James; P G Kopelman; M E Lean; G Williams
Journal:  Int J Obes Relat Metab Disord       Date:  2000-03

Review 6.  Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity.

Authors:  Nicholas T Bello; Matthew R Zahner
Journal:  Curr Opin Investig Drugs       Date:  2009-10

7.  The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?

Authors:  Steven Woloshin; Lisa M Schwartz
Journal:  JAMA Intern Med       Date:  2014-04       Impact factor: 21.873

8.  Combination phentermine and topiramate for weight maintenance: the first Australian experience.

Authors:  Sandra L Neoh; Priya Sumithran; Cilla J Haywood; Christine A Houlihan; Fiona T H Lee; Joseph Proietto
Journal:  Med J Aust       Date:  2014-08-18       Impact factor: 7.738

9.  Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.

Authors:  A Astrup; R Carraro; N Finer; A Harper; M Kunesova; M E J Lean; L Niskanen; M F Rasmussen; A Rissanen; S Rössner; M J Savolainen; L Van Gaal
Journal:  Int J Obes (Lond)       Date:  2011-08-16       Impact factor: 5.095

10.  Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques.

Authors:  Paul Kievit; Heather Halem; Daniel L Marks; Jesse Z Dong; Maria M Glavas; Puspha Sinnayah; Lindsay Pranger; Michael A Cowley; Kevin L Grove; Michael D Culler
Journal:  Diabetes       Date:  2012-10-09       Impact factor: 9.461

View more
  1 in total

1.  Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity.

Authors:  Joyce Huang; Michelle Pham; William J Panenka; William G Honer; Alasdair M Barr
Journal:  Front Psychiatry       Date:  2022-05-18       Impact factor: 5.435

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.